Saturday 17 October 2026
Export VINC’s income statement to Excel — free account
Vincerx Pharma, Inc.
VINC Healthcare Biotechnology
In the quarter to March 2025, EPS grew 87.9% and free cash flow grew 42.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.02
0.01
−33.33%
Follow VINC
| Older periods | Jun '24 | Sep '24 | Dec '24 | Mar '25 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
3.43 | 2.17 | 1.21 | 1.79 |
Net Debt/EBITDA |
2.31 | 1.32 | 0.59 | 1.36 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.22 | 0.81 | 0.77 | 0.89 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(3.04) | (2.79) | (3.26) | (1.24) | |
Cash per Share |
8.56 | 4.45 | 2.67 | 1.26 | |
Shareholders Equity per Share |
8.06 | 3.99 | 1.44 | 0.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.06 | 3.99 | 1.44 | 0.58 | |
Free Cash Flow |
(5.83) | (6.38) | (6.18) | (4.45) | |
Working Capital |
12.95 | 6.32 | 1.13 | 2.07 | |
Net Current Asset Value |
12.20 | 5.91 | 1.13 | 2.07 | |
| Other line items | |||||
Quick Ratio |
3.27 | 2.07 | 1.16 | 1.72 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.04) | (2.79) | (3.26) | (1.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
1.20 | 1.06 | 1.04 | — | |
Average Payables |
2.53 | 2.51 | 2.26 | 2.29 | |
Average Assets |
28.40 | 20.61 | 13.11 | 7.88 | |
Average Common Equity |
19.79 | 12.42 | 6.97 | 0.72 |
Columns are period end dates